NASDAQ · DSGN
Healthcare · Biotechnology
$12.24
Up+$0.10 (+0.82%)
Updated Oct 2, 2026, 11:33 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DSGN
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 1, 2026
DSGN closed at $12.24 after 19 trading sessions, down 19.15% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 1, 2026 | $12.50 | $12.82 | $12.21 | $12.24 | 346.59K |
| Sep 30, 2026 | $12.70 | $12.82 | $12.40 | $12.57 | 589.52K |
| Sep 29, 2026 | $12.505 | $12.75 | $12.02 | $12.62 | 655.8K |
| Sep 28, 2026 | $12.09 | $12.4864 | $11.85 | $12.36 | 433.13K |
| Sep 25, 2026 | $12.29 | $12.505 | $11.97 | $12.12 | 434.5K |
| Sep 24, 2026 | $12.32 | $12.32 | $11.832 | $12.24 | 459.74K |
| Sep 23, 2026 | $13.07 | $13.245 | $12.12 | $12.36 | 738.28K |
| Sep 22, 2026 | $12.41 | $13.295 | $12.40 | $13.16 | 506.54K |
| Sep 21, 2026 | $12.35 | $12.65 | $12.145 | $12.55 | 506.44K |
| Sep 18, 2026 | $12.81 | $12.88 | $12.24 | $12.24 | 2.55M |
| Sep 17, 2026 | $12.73 | $12.90 | $12.17 | $12.81 | 601.18K |
| Sep 16, 2026 | $12.34 | $12.86 | $12.22 | $12.505 | 985.14K |
| Sep 15, 2026 | $13.47 | $13.52 | $12.16 | $12.225 | 1.28M |
| Sep 14, 2026 | $14.71 | $14.76 | $13.43 | $13.52 | 1.26M |
| Sep 11, 2026 | $14.99 | $15.14 | $14.43 | $14.63 | 715.24K |
| Sep 10, 2026 | $14.81 | $15.00 | $14.508 | $14.80 | 653K |
| Sep 9, 2026 | $15.12 | $15.49 | $14.87 | $15.02 | 821.14K |
| Sep 8, 2026 | $15.00 | $15.39 | $14.71 | $15.23 | 775.06K |
| Sep 4, 2026 | $14.96 | $15.35 | $14.96 | $15.14 | 256.62K |
The latest Smart Investors Daily articles mentioning DSGN.
Company
Market Activity
Research & News
DSGN research
Company profile and research snapshot.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 4, 2026 | Oppenheimer | Outperform | — |
| Mar 16, 2026 | Jefferies | Buy | — |
| Mar 10, 2026 | RBC Capital | Outperform | — |
| Jan 7, 2026 | Oppenheimer | Outperform | — |
| Dec 3, 2025 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Nov 26, 2025
Design Therapeutics plans to initiate patient dosing for DT-818, a potential treatment for Myotonic Dystrophy Type-1, in the first half of 2026. The company has obtained ex-US regulatory clearance and is developing gene-targeted therapies for various genetic diseases.
Yahoo · Nov 26, 2025
CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming investor conferences: Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 3:30 p.m. ET in New York, NYEvercore 8th Annual Healthcare Conference on Thursday, December 4, 2025, at
Yahoo · Nov 20, 2025
Design Therapeutics' (DSGN) Friedreich Ataxia program could deliver meaningful clinical benefits and
247wallst.com · Nov 20, 2025
The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA) blew out its fiscal third-quarter results and offered strong forward guidance, though perhaps not as robust as Wall Street had hoped.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DSGN.
